Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia

被引：0
|
作者：
Yang, Kun [1 ,2 ]
Yang, Beibei [3 ]
Zhou, Yali [3 ]
Huang, Qiuying [3 ]
Yin, Xiaolin [3 ]
机构：
[1] Zigong First Peoples Hosp, Dept Hematol, Zigong, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[3] 923rd Hosp Joint Logist Support Force Peoples Libe, Dept Hematol, Nanning, Guangxi, Peoples R China
来源：
ANNALS OF HEMATOLOGY | 2025年
关键词：
NUP98-NSD1; FIT3-ITD; Acute myeloid leukemia; Selinexor; Hematopoietic stem cell transplantation; NUCLEOPORIN NUP98; FUSION;
D O I：
10.1007/s00277-025-06312-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Nucleoporin 98 (NUP98) fusion oncoproteins are associated with various hematologic malignancies. Acute myeloid leukemia (AML) with NUP98-NSD1 typically co-occurs with FLT3-ITD mutations, exhibiting poor initial responses to traditional chemotherapy. This case report describes a relapsed and refractory AML case co-expressing NUP98/NSD1 and FLT3/ITD after matched sibling haplo-identical allogeneic hematopoietic stem cell transplantation, achieving molecular remission with a salvage therapy combining selinexor, venetoclax, and azacitidine. To our knowledge, this is the first report demonstrating the effectiveness of this combination therapy for relapsed/refractory NUP98-NSD1+/FLT3-ITD + AML. This report highlights the potential synergy between selinexor and established AML therapies, suggesting a promising approach to improve outcomes for refractory AML patients.
引用
收藏
页码：2545 / 2549
页数：5
相关论文
共 50 条
  • [41] Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia
    De Bellis, Eleonora
    Ottone, Tiziana
    Mercante, Lisa
    Falconi, Giulia
    Cugini, Elisa
    Consalvo, Maria Irno
    Travaglini, Serena
    Paterno, Giovangiacinto
    Piciocchi, Alfonso
    Rossi, Elisa Linnea Lindfors
    Gurnari, Carmelo
    Maurillo, Luca
    Buccisano, Francesco
    Arcese, William
    Voso, Maria Teresa
    LEUKEMIA RESEARCH, 2020, 99
  • [42] Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia
    Liu, Long-long
    Zhang, Dong-hua
    Mao, Xia
    Zhang, Xin-hua
    Zhang, Bing
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 446 (01) : 280 - 285
  • [43] Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
    Martinez-Cuadron, David
    Serrano, Josefina
    Mariz, Jose
    Gil, Cristina
    Tormo, Mar
    Martinez-Sanchez, Pilar
    Rodriguez-Arboli, Eduardo
    Garcia-Boyero, Raimundo
    Rodriguez-Medina, Carlos
    Martinez-Chamorro, Carmen
    Polo, Marta
    Bergua, Juan
    Aguiar, Eliana
    Amigo, Maria L.
    Herrera, Pilar
    Alonso-Dominguez, Juan M.
    Bernal, Teresa
    Espadana, Ana
    Sayas, Maria J.
    Algarra, Lorenzo
    Vidriales, Maria B.
    Vasconcelos, Graca
    Vives, Susana
    Perez-Encinas, Manuel M.
    Lopez, Aurelio
    Noriega, Victor
    Garcia-Fortes, Maria
    Chillon, Maria C.
    Rodriguez-Gutierrez, Juan, I
    Calasanz, Maria J.
    Labrador, Jorge
    Lopez, Juan A.
    Boluda, Blanca
    Rodriguez-Veiga, Rebeca
    Martinez-Lopez, Joaquin
    Barragan, Eva
    Sanz, Miguel A.
    Montesinos, Pau
    CANCERS, 2022, 14 (11)
  • [44] FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing
    Lee, Jong-Mi
    Park, Silvia
    Hwang, Insik
    Kang, Dain
    Cho, Byung Sik
    Kim, Hee-Je
    Ahn, Ari
    Kim, Myungshin
    Kim, Yonggoo
    CANCERS, 2022, 14 (24)
  • [45] Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
    Jentzsch, Madlen
    Bischof, Lara
    Brauer, Dominic
    Backhaus, Donata
    Ussmann, Jule
    Franke, Georg-Nikolaus
    Vucinic, Vladan
    Platzbecker, Uwe
    Schwind, Sebastian
    CANCERS, 2023, 15 (04)
  • [46] Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines
    Dayal, Neetu
    Opoku-Temeng, Clement
    Hernandez, Delmis E.
    Sooreshjani, Moloud Aflaki
    Carter-Cooper, Brandon A.
    Lapidus, Rena G.
    Sintim, Herman O.
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (07) : 823 - 835
  • [47] Autophagy and inflammasome activation are associated with poor response to FLT3 inhibitors in patients with FLT3-ITD acute myeloid leukemia
    de Macedo, Brunno Gilberto Santos
    de Melo, Manuela Albuquerque
    Pereira-Martins, Diego Antonio
    Machado-Neto, Joao Agostinho
    Traina, Fabiola
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [48] Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway
    Wang, Fangfang
    Huang, Jingcao
    Guo, Tingting
    Zheng, Yuhuan
    Zhang, Li
    Zhang, Dan
    Wang, Fujue
    Naren, Duolan
    Cui, Yushan
    Liu, Xiaoyan
    Qu, Ying
    Luo, Hongmei
    Yang, Yan
    Wei, Haichen
    Guo, Yong
    BIOCHEMICAL PHARMACOLOGY, 2021, 188
  • [49] FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia
    Tan, Yuxin
    Xin, Lilan
    Wang, Qian
    Xu, Rong
    Tong, Xiqin
    Chen, Guopeng
    Ma, Linlu
    Yang, Fuwei
    Jiang, Hongqiang
    Zhang, Nan
    Wu, Jinxian
    Li, Xinqi
    Guo, Xinyi
    Wang, Chao
    Zhou, Haibing
    Zhou, Fuling
    CANCER LETTERS, 2024, 592
  • [50] Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia
    Liu, Song-Bai
    Qiu, Qiao-Cheng
    Bao, Xie-Bing
    Ma, Xiao
    Li, Hong-Zhi
    Liu, Yue-Jun
    Chen, Su-Ning
    Song, Yao-Hua
    Wu, De-Pei
    Xue, Sheng-Li
    CANCER SCIENCE, 2018, 109 (12) : 3981 - 3992
12345